FOXP3 and neoplasm: Overall CD8+ T cell infiltration was associated with clinical benefit (P = 0.026) in contrast to tumor infiltration with regulatory T cells (FoxP3+) or CD8+/FoxP3 ratio, which were not (Fig. 3b).